Hirundo Biosciences

Hirundo Biosciences is a biotechnology company focused on developing next-generation therapeutics that target the DNA Damage Response (DDR) pathway. Co-founded by renowned Harvard geneticist Dr. David Sinclair, the company leverages a proprietary platform to identify small molecules that can modulate DNA repair mechanisms to treat cancer and potentially address aging-related pathologies. By selectively inhibiting or enhancing specific DNA repair enzymes, Hirundo aims to improve the efficacy of existing cancer treatments and develop novel monotherapies for genomic instability-driven diseases. The company is currently in the pre-clinical stage, advancing a pipeline of small molecule candidates designed to exploit synthetic lethality in tumor cells.